A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Admilparant (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 15 Sep 2023 Status changed from not yet recruiting to completed.
- 12 Apr 2023 New trial record